Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabet More

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Radiation Research|February 12, 2021
Developing Tumor Radiosensitivity Signatures Using LncRNAsMairah T Khan, Lingjian Yang, Elisabet More, et al.
BMC Urology|July 2, 2021
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancerBecky A S Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, et al.
Molecular Medicine Reports|June 22, 2022
Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signatureTim A D Smith, Brian Lane, Elisabet More, et al.
International Journal of Radiation Oncology, Biology, Physics|December 10, 2023
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD)David J Thomson, Nick J Slevin, Helen Baines, et al.
Ebiomedicine|February 22, 2024
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trialTim A D Smith, Catharine M L West, Nuradh Joseph, et al.
International Journal of Radiation Oncology, Biology, Physics|October 18, 2024
Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation TherapyMark D Reardon, Becky A S Bibby, Niluja Thiruthaneeswaran, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Radiation Research|February 12, 2021
Developing Tumor Radiosensitivity Signatures Using LncRNAsMairah T Khan, Lingjian Yang, Elisabet More, et al.
BMC Urology|July 2, 2021
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancerBecky A S Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, et al.
Molecular Medicine Reports|June 22, 2022
Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signatureTim A D Smith, Brian Lane, Elisabet More, et al.
International Journal of Radiation Oncology, Biology, Physics|December 10, 2023
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD)David J Thomson, Nick J Slevin, Helen Baines, et al.
Ebiomedicine|February 22, 2024
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trialTim A D Smith, Catharine M L West, Nuradh Joseph, et al.
International Journal of Radiation Oncology, Biology, Physics|October 18, 2024
Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation TherapyMark D Reardon, Becky A S Bibby, Niluja Thiruthaneeswaran, et al.
Pageof 1